BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiology’s ‘ESC Congress 2020’
September 15 2020 - 10:00AM
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the
"Company"), a medical technology company developing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced a scientific abstract and poster entitled,
"A novel cardiac signal processing system for electrophysiology
procedures: early insights from the PURE EP 2.0 study" is available
electronically from August 30th at the ESC Congress 2020 – The
Digital Experience.
The abstract is co-authored by Carola Gianni, M.D., Amin
Al-Ahmad, M.D., Shane M. Bailey, M.D., G. Joseph Gallinghouse,
M.D., Rodney P. Horton, M.D. and Andrea Natale, M.D. of the Texas
Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center
in Austin, TX. The independent, blinded reviewers were Bradley P.
Knight, M.D. (Northwestern University), Wendy Tzou, M.D.
(University of Colorado), and Pasquale Santangeli, M.D. (University
of Pennsylvania).
Identical electrocardiographic and intracardiac signal data were
recorded during 15 atrial fibrillation ablation procedures from the
PURE EP™ System, the signal recording system, and the 3D mapping
system. The collected signals underwent blinded, controlled
evaluation by three independent electrophysiologists to determine
whether the PURE EP™ signals are a viable alternative to
conventional sources and if it provides additional or clearer
diagnostic information. Reviewers were asked to record the quality
of each signal sample on a scale of 1-10 and select a rationale for
their rating in a dropdown menu.
Based on the ratings for each pair of signals, a cumulative
total of 29 PURE EP™ signals out of 34 (85.3%) were rated as
statistically equivalent or better for this dataset. In 35.5% of
samples, the reviewers selected PURE EP™ data because "more signal
components were visible." The abstract concludes that the PURE EP™
System is able to produce reliable and high-quality signals when
compared to the available standard of care systems.
“BioSig Technologies is very pleased to see some of the early
results from the PURE EP™ study shared during ESC 2020. We greatly
appreciate the scientific collaboration with the team at TCAI and
the independent EP reviewers. The PURE EP™ study is on-going, and
we look forward to sharing multi-center data with the EP community
in the coming months," commented Julie Stephenson, VP of Clinical
Affairs at BioSig Technologies, Inc.
Exceptionally, this year, the online event is available at no
charge, but pre-registration is required:Register for the ESC
Congress 2020 – The Digital Experience
About ESC Congress 2020 The European Society of
Cardiology (ESC) is an independent, non-profit organization. Its
members and decision-makers are busy healthcare professionals who
volunteer their time and expertise. The ESC represents more than
95,000 men and women in the field of cardiology from Europe, the
Mediterranean Basin, and far beyond. Due to the COVID-19 pandemic,
the government in the Netherlands has banned all meetings until
September 1. As Amsterdam was to be the host city, it is no longer
possible for ESC Congress to take place as planned. However, the
ESC remains committed to delivering practice-changing science to
the cardiology community and looks forward to bringing you 'ESC
Congress 2020 - The Digital Experience'.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company's first product, PURE EP (tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains "forward-looking statements." Such
statements may be preceded by the words "intends," "may," "will,"
"plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential" or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company's control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the
Company's Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC's website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024